Pancreatic Cancer Research

ResearcherSeoul National UniversityNo recent work listed

Yoonhyeong Byun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4258-891X; OpenAlex author ID A5067532944. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2019: 1 paper · 2020: 5 papers · 2021: 5 papers · 2022: 2 papers · 2023: 1 paper

Papers 14

  1. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. Co-author DOI 10.1002/jhbp.986↗
  2. Preoperative carbohydrate antigen 19-9 and standard uptake value of positron emission tomography-computed tomography as prognostic markers in patients with pan… Co-author DOI 10.1002/jhbp.845↗
  3. Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/cancers14184360↗
  4. Peritumoral lymph nodes in pancreatic cancer revisited; is it truly equivalent to lymph node metastasis? Co-author DOI 10.1002/jhbp.940↗
  5. Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.3.144↗
  6. CORRIGENDUM: Addition of data source: Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.4.252↗
  7. Comparison of perioperative short-term outcomes and oncologic long-term outcomes between open and laparoscopic distal pancreatectomy in patients with pancreati… Co-author DOI 10.4174/astr.2021.100.6.320↗
  8. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. First author DOI 10.5009/gnl20070↗
  9. Is the New T1 Category as Defined in the Eighth Edition of the AJCC Pancreatic Cancer Staging System an Improvement? Co-author DOI 10.1007/s11605-019-04464-x↗
  10. Multi-Biomarker Panel Prediction Model for Diagnosis of Pancreatic Cancer: a retrospective and multi-center cohort study Co-author DOI 10.21203/rs.3.rs-76136/v1↗
  11. Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker. Co-author DOI 10.3389/fonc.2020.616440↗
  12. Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12061443↗
  13. The Role of Location of Tumor in the Prognosis of the Pancreatic Cancer. Co-author DOI 10.3390/cancers12082036↗
  14. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. Co-author DOI 10.1002/jhbp.648↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐Young Jang · 14 shared papers, 2019–2023 · strength 1.61
  2. Wooil Kwon · 14 shared papers, 2019–2023 · strength 1.61
  3. Hongbeom Kim · 13 shared papers, 2019–2023 · strength 1.47
  4. Jae Seung Kang · 10 shared papers, 2019–2023 · strength 1.13
  5. Yoo Jin Choi · 8 shared papers, 2019–2022 · strength 0.95
  6. Seungyeoun Lee · 5 shared papers, 2020–2023 · strength 0.50
  7. Taesung Park · 5 shared papers, 2020–2023 · strength 0.50
  8. Joo Kyung Park · 5 shared papers, 2020–2023 · strength 0.50
  9. Jin Seok Heo · 4 shared papers, 2020–2023 · strength 0.40
  10. Junghyun Namkung · 4 shared papers, 2020–2023 · strength 0.40
  11. Woo Jin Lee · 4 shared papers, 2020–2023 · strength 0.40
  12. Chang Moo Kang · 4 shared papers, 2020–2023 · strength 0.40
  13. Joon Oh Park · 4 shared papers, 2020–2023 · strength 0.40
  14. Song Cheol Kim · 4 shared papers, 2020–2023 · strength 0.40
  15. Mirang Lee · 2 shared papers, 2020–2022 · strength 0.26
  16. Hyeong Seok Kim · 2 shared papers, 2021–2022 · strength 0.25
  17. In Woong Han · 2 shared papers, 2020–2023 · strength 0.20
  18. Huisong Lee · 2 shared papers, 2020–2023 · strength 0.20
  19. Eunsung Jun · 2 shared papers, 2020–2023 · strength 0.20
  20. Doo‐Ho Lee · 2 shared papers, 2020–2023 · strength 0.20
  21. Do‐Youn Oh · 2 shared papers, 2019–2021 · strength 0.20
  22. Sang Hyub Lee · 2 shared papers, 2019–2021 · strength 0.20
  23. Ji Kon Ryu · 2 shared papers, 2019–2021 · strength 0.20
  24. Sun‐Whe Kim · 2 shared papers, 2019–2020 · strength 0.19
  25. Do Kyoon Moon · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.